High Myc expression and transcription activity underlies intra-tumoral heterogeneity in triple-negative breast cancer

We have previously identified a novel intra-tumoral dichotomy in triple-negative breast cancer (TNBC) based on the differential responsiveness to a reporter containing the Sox2 regulatory region-2 (SRR2), with reporter responsive (RR) cells being more stem-like than reporter unresponsive (RU) cells. Using bioinformatics, we profiled the protein-DNA binding motifs of SRR2 and identified Myc as one of the potential transcription factors driving SRR2 activity. In support of its role, Myc was found to be highly expressed in RR cells as compared to RU cells. Enforced expression of MYC in RU cells resulted in a significant increase in SRR2 activity, Myc-DNA binding, proportion of cellsexpressing CD44+/CD24–, chemoresistance and mammosphere formation. Knockdown of Myc using siRNA in RR cells led to the opposite effects. We also found evidence that the relatively high ERK activation in RR cells contributes to their high expression of Myc and stem-like features. Using confocal microscopy and patient samples, we found a co-localization between Myc and CD44 in the same cell population. Lastly, a high proportion of Myc-positive cells in tumors significantly correlated with a short patient survival. In conclusion, inhibition of the MAPK/ERK/Myc axis may be an effective approach in eliminating stem-like cells in TNBC.

[1]  E. Li,et al.  The PI3K/AKT/c‐MYC Axis Promotes the Acquisition of Cancer Stem‐Like Features in Esophageal Squamous Cell Carcinoma , 2016, Stem cells.

[2]  P. Swanson,et al.  New MYC IHC Classifier Integrating Quantitative Architecture Parameters to Predict MYC Gene Translocation in Diffuse Large B-Cell Lymphoma , 2016, Applied immunohistochemistry & molecular morphology : AIMM.

[3]  G. Ball,et al.  MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours , 2016, British Journal of Cancer.

[4]  J. Lieberman,et al.  The Rab2A GTPase Promotes Breast Cancer Stem Cells and Tumorigenesis via Erk Signaling Activation , 2015, Cell reports.

[5]  N. Kneteman,et al.  Triple negative breast cancers comprise a highly tumorigenic cell subpopulation detectable by its high responsiveness to a Sox2 regulatory region 2 (SRR2) reporter , 2015, Oncotarget.

[6]  Qiu-ying Liu,et al.  Sp1 and c-Myc modulate drug resistance of leukemia stem cells by regulating survivin expression through the ERK-MSK MAPK signaling pathway , 2015, Molecular Cancer.

[7]  K. Gopal,et al.  Profiling gene promoter occupancy of Sox2 in two phenotypically distinct breast cancer cell subsets using chromatin immunoprecipitation and genome-wide promoter microarrays , 2014, Breast Cancer Research.

[8]  J. Dopazo,et al.  The Activation of the Sox2 RR2 Pluripotency Transcriptional Reporter in Human Breast Cancer Cell Lines is Dynamic and Labels Cells with Higher Tumorigenic Potential , 2014, Front. Oncol..

[9]  S. Thorgeirsson,et al.  MYC activates stem-like cell potential in hepatocarcinoma by a p53-dependent mechanism. , 2014, Cancer research.

[10]  M. Ando,et al.  Activated PI3K/AKT and MAPK pathways are potential good prognostic markers in node-positive, triple-negative breast cancer. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  C. Creighton,et al.  VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2 , 2014, Oncogene.

[12]  M. Glukhova,et al.  Myc is required for β-catenin-mediated mammary stem cell amplification and tumorigenesis , 2013, Molecular Cancer.

[13]  Phillip Owens,et al.  Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancer. , 2013, Cancer research.

[14]  Yupo Ma,et al.  Identification of two novel phenotypically distinct breast cancer cell subsets based on Sox2 transcription activity. , 2012, Cellular signalling.

[15]  M. Hitt,et al.  Aberrant expression and biological significance of Sox2, an embryonic stem cell transcriptional factor, in ALK-positive anaplastic large cell lymphoma , 2012, Blood Cancer Journal.

[16]  M. Glukhova,et al.  The Proto‐Oncogene Myc Is Essential for Mammary Stem Cell Function , 2012, Stem cells.

[17]  Hui-Kuan Lin,et al.  Activation of Ras/PI3K/ERK pathway induces c-Myc stabilization to upregulate argininosuccinate synthetase, leading to arginine deiminase resistance in melanoma cells. , 2012, Cancer research.

[18]  Irmtraud M. Meyer,et al.  The clonal and mutational evolution spectrum of primary triple-negative breast cancers , 2012, Nature.

[19]  Marc E. Lenburg,et al.  MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition , 2012, The Journal of experimental medicine.

[20]  Shuji Ogino,et al.  Differential WNT activity in colorectal cancer confers limited tumorigenic potential and is regulated by MAPK signaling. , 2012, Cancer research.

[21]  Y. Hoki,et al.  Crucial Role of C‐Myc in the Generation of Induced Pluripotent Stem Cells , 2011, Stem cells.

[22]  X. Chen,et al.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.

[23]  J. Mackey,et al.  DEAD box 1: a novel and independent prognostic marker for early recurrence in breast cancer , 2011, Breast Cancer Research and Treatment.

[24]  E. Henson,et al.  Epidermal growth factor regulates Mcl-1 expression through the MAPK-Elk-1 signalling pathway contributing to cell survival in breast cancer , 2011, Oncogene.

[25]  Jorge S Reis-Filho,et al.  Triple-negative breast cancer. , 2010, The New England journal of medicine.

[26]  Olufunmilayo I Olopade,et al.  MYC and Breast Cancer. , 2010, Genes & cancer.

[27]  R. Huang,et al.  Epithelial-Mesenchymal Transitions in Development and Disease , 2009, Cell.

[28]  David J. Nott,et al.  Meta-Analysis and Gene Set Enrichment Relative to ER Status Reveal Elevated Activity of MYC and E2F in the “Basal” Breast Cancer Subgroup , 2009, PloS one.

[29]  Hui Wang,et al.  c-Myc Is Required for Maintenance of Glioma Cancer Stem Cells , 2008, PloS one.

[30]  R. Eisenman,et al.  Myc's broad reach. , 2008, Genes & development.

[31]  Susan G Hilsenbeck,et al.  Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. , 2008, Journal of the National Cancer Institute.

[32]  Robin L. Jones,et al.  MYC amplification in breast cancer: a chromogenic in situ hybridisation study , 2006, Journal of Clinical Pathology.

[33]  B. Lüscher,et al.  The Ins and Outs of MYC Regulation by Posttranslational Mechanisms* , 2006, Journal of Biological Chemistry.

[34]  M. Huang,et al.  A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia. , 2006, Experimental hematology.

[35]  Harikrishna Nakshatri,et al.  CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis , 2006, Breast Cancer Research.

[36]  Kathryn A. O’Donnell,et al.  The c-Myc target gene network. , 2006, Seminars in cancer biology.

[37]  Ziqiu Wang,et al.  Phosphorylation regulates Myc expression via prolonged activation of the mitogen‐activated protein kinase pathway , 2006, Journal of cellular physiology.

[38]  P. Schirmacher,et al.  c-myc Amplifications in primary breast carcinomas and their local recurrences , 2006, Journal of Clinical Pathology.

[39]  Danila Coradini,et al.  Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. , 2005, Cancer research.

[40]  Peter Schraml,et al.  Prognostic Relevance of Gene Amplifications and Coamplifications in Breast Cancer , 2004, Cancer Research.

[41]  M. J. van de Vijver,et al.  Association of C‐MYC amplification with progression from the in situ to the invasive stage in C‐MYC‐amplified breast carcinomas , 2003, The Journal of pathology.

[42]  S. Morrison,et al.  Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[43]  C. Schlotter,et al.  C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer , 2003, Breast Cancer Research.

[44]  Stella Pelengaris,et al.  c-MYC: more than just a matter of life and death , 2002, Nature Reviews Cancer.

[45]  H. Niwa,et al.  Identification of Sox-2 regulatory region which is under the control of Oct-3/4-Sox-2 complex. , 2002, Nucleic acids research.

[46]  A. Karmoliński,et al.  Amplification of c-myc gene and overexpression of c-Myc protein in breast cancer and adjacent non-neoplastic tissue. , 2001, Clinical biochemistry.

[47]  B. Trock,et al.  C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance , 2000, British Journal of Cancer.

[48]  D. Persons,et al.  Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization. , 1997, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.